Free Trial
→ Trump doesn’t give a damn (From Porter & Company) (Ad)

Merus Q4 2023 Earnings Report

Merus logo
$47.37 -0.26 (-0.55%)
As of 02/21/2025 04:00 PM Eastern
Earnings HistoryForecast

Merus EPS Results

Actual EPS
-$1.09
Consensus EPS
-$0.71
Beat/Miss
Missed by -$0.38
One Year Ago EPS
N/A

Merus Revenue Results

Actual Revenue
$8.94 million
Expected Revenue
$10.43 million
Beat/Miss
Missed by -$1.49 million
YoY Revenue Growth
N/A

Merus Announcement Details

Quarter
Q4 2023
Date
2/28/2024
Time
N/A

Conference Call Resources

Powered by Quartr

Merus Earnings Headlines

Merus’ petosemtamab granted Breakthrough Therapy designation by FDA
February 19 at 9:54 AM | markets.businessinsider.com
Merus’s Breakthrough in HNSCC: Buy Rating Backed by FDA Support and Promising Trial Data
February 19 at 7:13 AM | tipranks.com
Collect $7k per month from Tesla’s SECRET dividend
There's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a traditional dividend, there's a way to collect up to $7,013 per month from Tesla… starting as early as next month. This backdoor strategy is changing the game for smart investors. Want to see how it works?
February 22, 2025 | Investors Alley (Ad)
Merus NV (MRUS) Receives Second Breakthrough Therapy Designation for Petosemtamab in Head and ...
February 19 at 6:24 AM | gurufocus.com
Innate Pharma and Merus gets FDA Breakthrough Therapy Designation for their respective treatments
February 18, 2025 | msn.com
7MRUS : Merus Shares Are Up Today: What's Going On?
February 18, 2025 | benzinga.com
See More Merus Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Merus? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Merus and other key companies, straight to your email.

About Merus

Merus (NASDAQ:MRUS) N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

View Merus Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles